Aratana Therapeutics, Inc. (NASDAQ:PETX) – Equities research analysts at Jefferies Group boosted their Q3 2017 earnings per share (EPS) estimates for Aratana Therapeutics in a research note issued to investors on Monday. Jefferies Group analyst D. Gu now anticipates that the biopharmaceutical company will earn ($0.24) per share for the quarter, up from their previous forecast of ($0.25). Jefferies Group currently has a “Buy” rating and a $8.00 target price on the stock. Jefferies Group also issued estimates for Aratana Therapeutics’ Q4 2017 earnings at ($0.23) EPS, FY2017 earnings at ($1.07) EPS, Q1 2018 earnings at ($0.19) EPS, Q2 2018 earnings at ($0.13) EPS, Q3 2018 earnings at ($0.03) EPS, Q4 2018 earnings at ($0.03) EPS, FY2018 earnings at ($0.38) EPS, Q1 2019 earnings at ($0.12) EPS, Q2 2019 earnings at ($0.07) EPS and FY2020 earnings at $0.19 EPS.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.29) by $0.03. Aratana Therapeutics had a negative return on equity of 51.21% and a negative net margin of 642.93%. The company had revenue of $5.16 million for the quarter, compared to analyst estimates of $4.50 million. During the same period in the previous year, the company posted $0.61 earnings per share. The firm’s revenue was down 86.4% on a year-over-year basis.

WARNING: “Q3 2017 Earnings Estimate for Aratana Therapeutics, Inc. Issued By Jefferies Group (PETX)” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/17/q3-2017-earnings-estimate-for-aratana-therapeutics-inc-issued-by-jefferies-group-petx.html.

A number of other brokerages also recently issued reports on PETX. BidaskClub downgraded Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 8th. ValuEngine upgraded Aratana Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 25th. Zacks Investment Research downgraded Aratana Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 10th. Finally, Stifel Nicolaus cut their price target on Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, May 10th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. Aratana Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $9.50.

Shares of Aratana Therapeutics (NASDAQ PETX) opened at 5.52 on Thursday. Aratana Therapeutics has a 52-week low of $4.97 and a 52-week high of $10.73. The company’s 50 day moving average price is $6.84 and its 200 day moving average price is $6.35. The company’s market capitalization is $237.37 million.

A number of hedge funds have recently modified their holdings of PETX. Financial Counselors Inc. purchased a new stake in shares of Aratana Therapeutics during the first quarter worth approximately $101,000. American International Group Inc. boosted its stake in shares of Aratana Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,354 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in shares of Aratana Therapeutics by 7.9% in the second quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 1,200 shares in the last quarter. Ray Gerald L & Associates Ltd. boosted its stake in shares of Aratana Therapeutics by 38.2% in the first quarter. Ray Gerald L & Associates Ltd. now owns 23,900 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 6,600 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY boosted its stake in shares of Aratana Therapeutics by 17.9% in the first quarter. Metropolitan Life Insurance Co. NY now owns 25,619 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 3,883 shares in the last quarter. 63.97% of the stock is owned by institutional investors.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.